A Review of the Current Landscape of Anti-Fibrotic Medicines
Fibrosis · 2024
DOI: 10.70322/fibrosis.2024.10005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fibrosis, 2024. Verfasst von Alice R. Lapthorn und 5 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Fibrosis is defined as the excessive accumulation and disorganized deposition of extracellular matrix components, affecting any organ in the human body. Fibrotic diseases of the vital organs such as lung, heart, kidney and liver can be chronic, progressive, irreversible and fatal. Although fibrotic diseases account for 45% of the mortality in the Western world, the available treatment options are limited in numbers, efficacy and safety. There is certainly a lack of progress in developing novel anti-fibrotics even though the market size for fibrotic diseases is estimated to be ~$30B and several pharmaceutical companies have active R&D programmes in this field. We reviewed the current efforts in developing novel anti-fibrotic medicines focusing on lung, heart, kidney, liver and skin fibrosis. Our analysis revealed an estimated 83% attrition rate from Phase 2 to Phase 3 trials across the five fibrotic diseases. The possible reasons for the slow pace and high attrition rates in developing new anti-fibrotics are discussed and potential solutions are proposed.
Zitieren
APA
Lapthorn, A. R., Harding, S. L., Feltham, K. M., Sathyananth, D., Salisbury, D. C., & Cellek, S. (2024). A Review of the Current Landscape of Anti-Fibrotic Medicines. Fibrosis. https://doi.org/10.70322/fibrosis.2024.10005
Vancouver
Lapthorn AR, Harding SL, Feltham KM, Sathyananth D, Salisbury DC, Cellek S. A Review of the Current Landscape of Anti-Fibrotic Medicines. Fibrosis. 2024. doi:10.70322/fibrosis.2024.10005
BibTeX
@article{Lapthorn2024,
author = {Lapthorn, Alice R. and Harding, Sophie L. and Feltham, Kieran M. and Sathyananth, Deepika and Salisbury, Daniel C. and Cellek, Selim},
title = {A Review of the Current Landscape of Anti-Fibrotic Medicines},
journal = {Fibrosis},
year = {2024},
doi = {10.70322/fibrosis.2024.10005}
}
EUVIMED